Adma Biologics Stock News

Brokerages forecast that ADMA Biologics, Inc. (NASDAQ:ADMA) will announce $21.93 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for ADMA Biologics earnings. The lowest sales estimate is $21.40 million and the highest is $22.60 million. ADMA Biologics reported sales of $13.96 million in the same quarter []

Check these penny stocks out for your watchlist The post Are These Penny Stocks on Your Watchlist Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

On November 10th, ADMA reported a great quarter. Revenue grew to $20.68M, up 101.2% y/y, and the Company reached a number of milestones.

Check these penny stocks out for your watchlist The post Are These Penny Stocks on Your Watchlist Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

ADMA Biologics Inc. (NASDAQ:ADMA) price on Friday, November 19, rose 2.73% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.50. A look at the stock’s price movement, the level at last check in today’s session was $1.46, moving within a range at $1.45 and $1.53. The beta … There Is A Lot Of Upside Potential For ADMA Biologics Inc.(NASDAQ: ADMA) Read More »

ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additiona

ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction

ADMA Biologics (NASDAQ:ADMA) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Monday, Zacks.com reports. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious []

ADMA Biologics Inc (NASDAQ: ADMA) achieved Q3 sales of $20.7 million, + 101% Y/Y, beating the consensus of $18.72 million. The increase was favorably impacted by the continued commercial ramp-up of

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q3 2021 Results - Earnings Call Transcript

Adma Biologics (ADMA) delivered earnings and revenue surprises of 13.33% and 11.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.

Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET

ADMA has been trading in a downward trajectory over the past few years. ADMA's stock price has taken a beating from several equity offerings as the business continues to invest in the future.

Penny stocks are seeing heightened momentum, which companies are you watching? The post Best Penny Stocks to Watch as The Market Turns Bullish appeared first on Penny Stocks to Buy, Picks, News and In